April 14th 2025
Vitrakvi (larotrectinib) was first granted accelerated approval by FDA in November 2018.
April 11th 2025
The company has plans to invest $23 billion during the next five years to expand manufacturing and R&D in the US, which will include seven new facilities.
April 8th 2025
Lack of skills in the AI realm was a distant second among those surveyed about the biggest barrier to innovation while using the technology.
Advancement of emerging therapies faces hurdles across all aspects and phases of drug development and manufacturing.
April 7th 2025
Advanced solutions are improving drug dissolution, absorption, and overall therapeutic performance.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Solid-Dosage Forms Demand Traditional and Emerging Technologies
Contract development and manufacturing organizations identify trends, challenges, and emerging technology and service needs for solid and semi-solid dosage forms.
Shifting Gears in Drug Development Outsourcing Responsibilities
For a bio/pharma industry in flux, contract services are playing a greater-and more diverse-role in drug development.
Study Shows Capsugel's Capsules as Suitable Excipients in QbD-based Product Development and Manufacturing
Study provides first substantive reference data on key quality attributes of empty capsules
Hovione Partners with Merrion Pharmaceuticals on Absorption-Enhancing Technology
Hovione will use Merrion's GIPET absorption-enhancing technology for solid-dosage drugs.
FDA Issues Warning Letter to Italian API Manufacturer
Trifarma cited for significant deviations in data collection and security, and employee training.
The Mainstreaming of Continuous Flow API Synthesis
The pharma industry is moving toward commercial-scale continuous processes for small-molecule API manufacturing.
Biotage Launches Accelerated Chromatographic Isolation
Biotage has launched a purification technology, Accelerated Chromatographic Isolation (ACI), which converts simple flash purification into a faster and more economical way to isolate pure compounds.
PolySciTech's SpinSwiper Could Speed Up Production of Controlled-Release Microparticles
PolySciTech's new launch, SpinSwiper, has the potential to speed up microparticle production.
Pharma Capacity to Produce Cytotoxic Injectable Drugs Constricts
PharmSource special report shows demand for cytotoxic injectable drugs could tap existing CMO capacity.
Advances in Controlled-Release Drug Delivery
Industry experts share their perspectives on key advances in controlled-release drug delivery and future innovations in this arena.
Seeking Alternative Catalyst Solutions
Transition metal-containing catalysts are widely used in organic synthesis, but many are based on expensive, rare metals. Researchers are seeking more sustainable alternatives.
DCAT Sharp Sourcing Addresses Procurement Topics
DCAT's Sharp Sourcing 2014 educational program offers pharmaceutical and biopharmaceutical companies a forum to gain best practice insights in sourcing and procurement.
HPAPIs: Fast-growing Segment Presents Challenges and Opportunities
Appropriate process design and engineering are critical for the production of small-molecule and biologic HPAPIs.
BPTF Warns FDA on Reduced API Manufacturer Inspections
The Bulk Pharmaceuticals Task Force asks FDA to respond to concerns about reduction in API facility compliance inspections.
Hospira Issues Recall Due to Particles from Glass Defects in Vials
Hospira has recalled one lot of labetalol hydrochloride injection, USP, due to visible particulates.
Advanced Aseptic Technology Provides Glass-Free Delivery of Injectable Drugs
Catalent's Advasept platform uses blow-fill-seal technology to aseptically manufacture, fill, and seal a polymeric primary container for injectable drugs.
Extractables and Leachables Testing
Industry experts discuss how extractables and leachables studies are designed using a risk-based approach.
Packaging Becomes Enabler for Biopharmaceuticals
Once an afterthought, packaging has now become an essential component of biopharmaceutical product development and marketing.
Boosting New Antibiotic Drug Development in Europe
With the rising threat of antibiotic resistance and a diminishing R&D pipeline for novel drugs, Europe must step up its game to address this growing problem.
Scientific Advances in Cocrystals are Offset by Regulatory Uncertainty
Drug developers are taking a wait-and-see approach to the use of cocrystals.
India's Developing Market Offers Opportunities
Biopharma companies should not overlook India's growing market.
Laser Diffraction Software Supports Analytical QbD
Gallus BioPharmaceuticals Enters Agreement with Omni Bio Pharmaceutical
Gallus BioPharmaceuticals enters a cell line optimization and manufacturing agreement with Omni Bio Pharmaceutical.
Safety by Design—Mitigating the Risk of Medication Errors Through Product Design
Experts share insights on how product appearance such as size, shape, color, and imprint can make a difference in reducing medication errors.
Controlled-Release Technologies Create Opportunities for Solid-Dosage Drug Formulators
Lifecycle management opportunities are impacting the development of controlled-release technologies for solid-dosage drugs.
A Practical Guide to Hot-Melt Extrusion Scale-Up for Pharmaceutical Applications
The author discusses various aspects of the hot-melt extrusion process and outlines a practical approach to scale-up.
Advances in Hot-Melt Extrusion Manufacturing
Charlie Martin, Leistritz Extrusion, describes hot-melt extrusion manufacturing processes and advances.
Obtaining User-Defined Particle Size Distribution Using Dry Granulation
The author examines the effect of compaction force, gap width, and sieve setup on granule size.
A Quality-by-Design Approach to Optimize In-Process Curing of EUDRAGIT NM 30 D
A study investigated the influence and correlation of critical process parameters for the optimization of in-process curing.
Selection of Excipients in Generic Formulations
The selection of excipients is important in generic formulations due to the impact it has on the risk and performance of generic drugs.